MTRAC Commissioning Support: Fixed-dose LABA/ICS inhalers for the treatment of COPD -

MTRAC Commissioning Support: Fixed-dose LABA/ICS inhalers for the treatment of COPD
Information type: Evidence summaries
Source: Midlands Therapeutics Review and Advisory Committee
Specialities: Respiratory disorders
Summary
The committee considered the established products Seretide Accuhaler® and Symbicort Turbohaler® had largest evidence base for efficacy; evidence for Fostair was also considered relatively strong. The evidence for Relvar Ellipta® was considered relatively weak.
UKMi comment
For three months following publication, only an excerpt of the guidance is available to non-subscribers. The full guidance will be publicly available after this time.
Related links: